DNA Wellness to Invest Rs 200 Crore for Cervical Cancer Screening Labs by 2027

DNA Wellness has announced an investment of Rs 200 crore to set up over 100 cervical cancer screening labs across India by 2027. The company will utilize the DNA Ploidy Test, also known as CERViSure, to offer quick and accurate cervical cancer detection. The first lab has been launched in Ahmedabad.

In a significant move towards enhancing cervical cancer screening, City-based DNA Wellness has committed to investing Rs 200 crore to establish over 100 labs across India by the year 2027.

The company has secured exclusive rights to the DNA Ploidy Test, a notable screening tool developed by the British Columbia Cancer Research Agency, Canada, which is known for its accuracy and non-invasive nature. Named CERViSure, the test promises quick and reliable cervical cancer detection.

The first CERViSure laboratory has already been inaugurated in Ahmedabad, Gujarat, addressing the critical need for easily accessible screening facilities. According to Co-founder Pathik Bhandari, further expansions include dedicated labs in Ahmedabad, Vadodara, Rajkot, and Surat by October 2024, and nationwide collaborations with hospitals and clinics to maximize patient reach.

(With inputs from agencies.)